发明名称 |
AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES |
摘要 |
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided. |
申请公布号 |
US2015050273(A1) |
申请公布日期 |
2015.02.19 |
申请号 |
US201414447751 |
申请日期 |
2014.07.31 |
申请人 |
Five Prime Therapeutics, Inc. |
发明人 |
Harding Thomas;Pierce Kristen;Patil Namrata;Brennan Thomas;Hambleton Julie |
分类号 |
C07K16/28 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. A composition comprising a plurality of anti-FGFR2IIIb antibodies, wherein each anti-FGFR2IIIb antibody comprises heavy chain and light chain variable regions, wherein the heavy chain variable region comprises:
(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6; (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7; and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8; and the light chain variable region comprises: (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9; (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10; and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11; wherein at least 95% of the anti-FGFR2IIIb antibodies in the composition are afucosylated. |
地址 |
South San Francisco CA US |